Literature DB >> 12477

Interaction of benzodiazepines with neuroleptics at central dopamine neurons.

H H Keller, R Schaffner, W Haefely.   

Abstract

Several benzodiazepines (chlordiazepoxide, clonazepam, diazepam and flunitrazepam) markedly counteracted the elevation of the homovanillic acid (HVA) content of the rat brain induced by neuroleptics (haloperidol, pimozide, chlorpromazine, and clozapine). A similar effect was obtained with the inhibitor of GABA transaminase, aminooxyacetic acid (AOAA). The interaction of benzodiazepines with the neuroleptic-induced HVA increase was similar in the striatum and in the limbic forebrain and was antagonized by the GABA receptor-blocking agent, picrotoxin. Both the benzodiazepines used and AOAA potentiated the cataleptic effect of the four neuroleptics. It is concluded that benzodiazepines, by intensifying GABA-ergic transmission, enhance the ongoing inhibition of mesencephalic dopamine neurons exerted by the striatonigral GABA system. As a consequence, the feedback activation of dopamine neurons induced by the neuroleptic blockade of dopamine receptors in the striatum and the limbic system is attenuated. This results in a reduction of the neuroleptic-induced increase of HVA and in the potentiation of the cataleptic effect of neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 12477     DOI: 10.1007/BF00692778

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

1.  Determination of nanogram amounts of homovanillic acid in the central nervous system with a rapid semiautomated fluorometric method.

Authors:  B H Westerink; J Korf
Journal:  Biochem Med       Date:  1975-02

Review 2.  New concepts on the mechanism of action of benzodiazepines.

Authors:  E Costa; A Guidotti; C C Mao; A Suria
Journal:  Life Sci       Date:  1975-07-15       Impact factor: 5.037

3.  On the source of GABA-containing terminals in the substantia nigra. Electron microscopic autoradiographic and biochemical studies.

Authors:  T Hattori; P L McGeer; H C Fibiger; E G McGeer
Journal:  Brain Res       Date:  1973-05-17       Impact factor: 3.252

4.  Potentiation of phenothiazines by -methyltyrosine in treatment of chronic schizophrenia.

Authors:  A Carlsson; T Persson; B E Roos; J Wålinder
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

5.  Origin and distribution of glutamate decarboxylase in substantia nigra of the cat.

Authors:  F Fonnum; I Grofová; E Rinvik; J Storm-Mathisen; F Walberg
Journal:  Brain Res       Date:  1974-05-10       Impact factor: 3.252

6.  The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique.

Authors:  R Laverty; K M Taylor
Journal:  Anal Biochem       Date:  1968-02       Impact factor: 3.365

7.  The effect of diazepam on spinal cord activities: possible sites and mechanisms of action.

Authors:  P Polc; H Möhler; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

8.  Effects of two benzodiazepines, phenobarbitone, and baclofen on synaptic transmission in the cat cuneate nucleus.

Authors:  P Polc; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-08       Impact factor: 3.000

9.  Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain.

Authors:  B H Westerink; J Korf
Journal:  Eur J Pharmacol       Date:  1975-08       Impact factor: 4.432

10.  The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the brain of the mouse.

Authors:  G F Murphy; D Robinson; D F Sharman
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

View more
  23 in total

1.  Rotational behaviour and cGMP responses following manipulation of nigral mechanisms with chlordiazepoxide. Evidence for enhancement of GABA transmission by benzodiazepines.

Authors:  J L Waddington; A Longden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

2.  The Dopamine Dilemma-Part II: Could Stimulants Cause Tolerance, Dependence, and Paradoxical Decompensation?

Authors:  Jason Yanofski
Journal:  Innov Clin Neurosci       Date:  2011-01

3.  Synaptic pharmacology of barbiturates and benzodiazepines.

Authors:  W E Haefely
Journal:  Agents Actions       Date:  1977-09

4.  Benzodiazepines and central inhibitory mechanisms.

Authors:  H M Geller; D A Taylor; B J Hoffer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-09       Impact factor: 3.000

5.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Anaesthesia abolishes the effect of valproate on extracellular 5-HIAA, DOPAC and ascorbate as measured in rat striatum by differential pulse voltammetry.

Authors:  F Crespi; P E Keane; M Morre
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

7.  On the mode of action of diazepam on brain catecholamine metabolism.

Authors:  B Biswas; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-05       Impact factor: 3.000

Review 8.  Benzodiazepines and anterior pituitary function.

Authors:  E Arvat; R Giordano; S Grottoli; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

9.  Effects of diazepam on behavior and dopamine-containing substantia nigra units in freely moving cats.

Authors:  M E Trulson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Effect of neuroleptics and other drugs on monoamine uptake by membranes of adrenal chromaffin granules.

Authors:  A Pletscher
Journal:  Br J Pharmacol       Date:  1977-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.